Dong et al., 2014 - Google Patents
Vitamin E analogues as prototypic mitochondria-targeting anti-cancer agentsDong et al., 2014
- Document ID
- 12234958775110656946
- Author
- Dong L
- Neuzil J
- Publication year
- Publication venue
- Mitochondria: The Anti-Cancer Target for the Third Millennium
External Links
Snippet
Mitochondria have emerged recently as a novel, intriguing target for anti-caner drugs, owing largely to their importance for proper growth of cancer cells. Destabilization of mitochondria often results in the induction of apoptosis in cancer cells that, consequently, may translate …
- 229930003427 Vitamin E 0 title abstract description 98
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bao et al. | Molecular mechanism of β-sitosterol and its derivatives in tumor progression | |
| Abraham et al. | Vitamin E and its anticancer effects | |
| Amjad et al. | A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound | |
| Shankar et al. | Plant flavone apigenin: An emerging anticancer agent | |
| Rashidi et al. | Anti‐atherosclerotic effects of vitamins D and E in suppression of atherogenesis | |
| Wang et al. | The roles of curcumin in regulating the tumor immunosuppressive microenvironment | |
| Iqbal et al. | Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications | |
| Wojcik et al. | A review of natural and synthetic antioxidants important for health and longevity | |
| Liao et al. | Naringenin inhibits migration of bladder cancer cells through downregulation of AKT and MMP-2 | |
| Liao et al. | Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549 | |
| Das Gupta et al. | Tocopherols in cancer: An update | |
| Silva et al. | Phytic acid: from antinutritional to multiple protection factor of organic systems | |
| Ledesma et al. | Selenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status | |
| Angulo-Molina et al. | The role of alpha tocopheryl succinate (α-TOS) as a potential anticancer agent | |
| Ono et al. | Mechanism of the anticancer effect of lycopene (tetraterpenoids) | |
| Vernousfaderani et al. | Resveratrol and colorectal cancer: a molecular approach to clinical researches | |
| EP2265623B1 (en) | Mitochondrially delivered anti-cancer compounds | |
| Dabydeen et al. | Genetically engineered ERα-positive breast cancer mouse models | |
| Shibata et al. | δ-Tocotrienol suppresses VEGF induced angiogenesis whereas α-tocopherol does not | |
| Bala et al. | Revitalizing allicin for cancer therapy: advances in formulation strategies to enhance bioavailability, stability, and clinical efficacy | |
| Johnson et al. | Dietary factors and pancreatic cancer: the role of food bioactive compounds | |
| Duan et al. | A review on dietary flavonoids as modulators of the tumor microenvironment | |
| Yang et al. | Targeting of non-apoptotic cancer cell death mechanisms by quercetin: Implications in cancer therapy | |
| Pandey et al. | Deciphering the modulatory role of apigenin targeting oncogenic pathways in human cancers | |
| Verma et al. | Recent advances and future directions in etiopathogenesis and mechanisms of reactive oxygen species in cancer treatment |